NCT05615142 is a Phase 1 clinical trial of Low Dose Radiotherapy in NSCLC, sponsored by Sichuan University.

Who is sponsoring NCT05615142?

NCT05615142 is sponsored by Sichuan University.

What drugs are being tested in NCT05615142?

Interventions in NCT05615142: Low Dose Radiotherapy, stereotactic body radiation therapy, PD-1 Inhibitors.

What condition does NCT05615142 study?

NCT05615142 studies NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor.

Is NCT05615142 still recruiting?

NCT05615142 is currently recruiting now. Last updated 17 April 2024.

Last reviewed 2024-04-17 · How we verify

NCT05615142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Recruiting now Phase 1 Last updated 17 April 2024

What this trial tests

Phase 1 trial testing Low Dose Radiotherapy in NSCLC in 9 participants. Currently enrolling.

Timeline

15 December 2021

Primary endpoint
30 June 2025

31 December 2026

Quick facts

Lead sponsor	Sichuan University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	15 December 2021
Primary completion	30 June 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Low Dose Radiotherapy
stereotactic body radiation therapy — full drug profile →
PD-1 Inhibitors — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
Low Dose Radiotherapy — all drugs for Low Dose Radiotherapy →
Stereotactic Body Radiotherapy — all drugs for Stereotactic Body Radiotherapy →
PD-1 Inhibitor — all drugs for PD-1 Inhibitor →

Sponsor

Sichuan University

Who can join

18 and older, any sex, with NSCLC or Low Dose Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot phase I trial aims to investigate the safety and tolerability of low dose radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in combination with programmed cell death-1 (PD-1) inhibitors in Stage IV non-small cell lung cancer (NSCLC) patients who have failed standard therapy. At least 9 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.
Liang X, Li F, Zhang Y, Hu P, et al · · 2026 · PMID 41982689 · DOI 10.21037/tlcr-2026-1-0018

Verify or expand the search:

Other trials of Low Dose Radiotherapy

Trials testing the same drug.

NCT06848465 — LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis · Phase 1 · recruiting
NCT06349837 — Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors · Phase 1 · recruiting
NCT04534790 — Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia · NA · completed
NCT03812549 — Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients · Phase 1 · completed
NCT03196778 — Low Dose Hemi-body Radiation For Recurrent Prostate Cancer · NA · completed

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Sichuan University trials

Trials by the same sponsor.

NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05615142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan University
Last refreshed: 17 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05615142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing